News & Updates

Show Multimedia Only
Optimal glycaemic control associated with lower pancreatic cancer risk in T2D
Optimal glycaemic control associated with lower pancreatic cancer risk in T2D
19 Sep 2025 byChristina Lau

In patients with type 2 diabetes (T2D), optimal glycaemic control is associated with lower risks of pancreatic cancer as well as pancreatic cancer–related mortality and all-cause mortality, a territory-wide population-based retrospective cohort study has shown.

Optimal glycaemic control associated with lower pancreatic cancer risk in T2D
19 Sep 2025
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
17 Sep 2025 byStephen Padilla

Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
17 Sep 2025